title: Conversion chemotherapy using cetuximab plus FOLFIRI followed by bevacizumab plus mFOLFOX6 in patients with unresectable liver metastases from colorectal cancer.
abstract: Recently, in patients with unresectable colorectal liver metastasis, liver resection sometimes becomes possible by intensive systemic chemotherapy, i.e. conversion therapy. However, among cases that do not respond well to first-line chemotherapy, it is rare that second-line chemotherapy results in a marked response allowing liver resection. We consider that the liver resection rate may be increased by initiating second-line treatment at an earlier stage before progression subsequent to first-line chemotherapy. We are conducting a multicentre Phase II study to evaluate the efficacy and safety of sequential chemotherapy using six cycles of cetuximab plus FOLFIRI (5-fluorouracil, folinic acid and irinotecan) followed by six cycles of bevacizumab plus FOLFOX (5-fluorouracil, folinic acid and oxaliplatin) as conversion chemotherapy. The primary endpoint is the liver resection rate during the bevacizumab + FOLFOX phase. Fifty patients are required for this study.
authors.affiliation: Division of Surgical Oncology, Department of Surgery, Nagoya Graduate School of Medicine, 65, Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan.
authors.forename: Keisuke
authors.initials: K
authors.lastname: Uehara
authors.forename: Seiji
authors.initials: S
authors.lastname: Ishiguro
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Hiramatsu
authors.forename: Hideki
authors.initials: H
authors.lastname: Nishio
authors.forename: Eiji
authors.initials: E
authors.lastname: Takeuchi
authors.forename: Daisuke
authors.initials: D
authors.lastname: Takahari
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Yoshioka
authors.forename: Yu
authors.initials: Y
authors.lastname: Takahashi
authors.forename: Tomoki
authors.initials: T
authors.lastname: Ebata
authors.forename: Kenichi
authors.initials: K
authors.lastname: Yoshimura
authors.forename: Kei
authors.initials: K
authors.lastname: Muro
authors.forename: Masato
authors.initials: M
authors.lastname: Nagino
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D000068818:Cetuximab; D017322:Clinical Trials, Phase II as Topic; D015179:Colorectal Neoplasms / Q000473:pathology*; D004334:Drug Administration Schedule; D064420:Drug-Related Side Effects and Adverse Reactions; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007564:Japan; D002955:Leucovorin / Q000009:adverse effects / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary* / Q000601:surgery; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use; D018579:Patient Selection
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D009944:Organoplatinum Compounds; D000068258:Bevacizumab; D000068818:Cetuximab; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin